ReviewPaediatric respiratory reviews2020
Bacille Calmette Guérin (BCG) and new TB vaccines: Specific, cross-mycobacterial and off-target effects.
Review in Paediatric respiratory reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07094711 (Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG in Patients With Mycobacterium Avium Complex Lung Disease), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG in Patients With Mycobacterium Avium Complex Lung Disease (BOOST)
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.The New England journal of medicine · 2023Trial
- BCG and beyond: unlocking new frontiers in TB vaccine development.Frontiers in immunology · 2025Review
- Effects of non-tuberculous mycobacteria on BCG vaccine efficacy: A narrative review.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Article
- Article
- Article
- Protective role of Bacillus Calmette-Guérin vaccine in Alzheimer's disease progression: A systematic review and meta-analysis.Heliyon · 2024Article
- Interpreting the Results of Trials of BCG Vaccination for Protection Against COVID-19.The Journal of infectious diseases · 2023Review
- IV BCG Vaccination and Aerosol BCG Revaccination Induce Mycobacteria-Responsive γδ T Cells Associated with Protective Efficacy againstVaccines · 2023Article
- COVID-19 and Tuberculosis: Unveiling the Dual Threat and Shared Solutions Perspective.Journal of clinical medicine · 2023Article
- Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection.Tropical medicine and infectious disease · 2023Review
- Delivery ofFrontiers in immunology · 2023Article
- Immunogenicity of Bacillus Calmette-Guérin in pigs: potential as a translational model of non-specific effects of BCG.Frontiers in immunology · 2023Article
- Observational
- Review
- BCG vaccination induces enhanced frequencies of memory T cells and altered plasma levels of common γc cytokines in elderly individuals.PloS one · 2021Article
- Cheap and Commonplace: Making the Case for BCG and γδ T Cells in COVID-19.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Bacille Calmette Guérin (BCG) vaccine was developed over a century ago and has become one of the most used vaccines without undergoing a modern vaccine development life cycle. Despite this, the vaccine has protected many millions from severe and disseminated forms of tuberculosis (TB). In addition, BCG has cross-mycobacterial effects against non-tuberculous mycobacteria and off-target (also called non-specific or heterologous) effects against other infections and diseases. More recently, BCG's effects on innate immunity suggest it might improve the immune response against viral respiratory infections including SARS-CoV-2. New TB vaccines, developed over the last 30 years, show promise, particularly in prevention of progression to disease from TB infection in young adults. The role of BCG in the context of new TB vaccines remains uncertain as most participants included in trials have been previously BCG immunised. BCG replacement vaccines are in efficacy trials and these may also have off-target effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.